Interferon-γ-mediated prevention of graft-versus-host disease: Development of immune competent and allo-tolerant T cells in chimeric mice

Bone Marrow Transplantation

Volumn 19, Issue 6, 1997, Pages 601-606

  Brok, H P M ^a,b   Vossen, J M ^a   Heidt, P J ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

Author keywords

Allo tolerance; BMT; GVHD; IFN

Indexed keywords

GAMMA INTERFERON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CHIMERA; CONTROLLED STUDY; DRUG POTENCY; FEMALE; GRAFT VERSUS HOST REACTION; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; INTRAPERITONEAL DRUG ADMINISTRATION; IRRADIATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE;

EID: 0030969766     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700707     Document Type: Article

References (39)

1. Van Bekkum DW. Graft-versus-host disease. In: Van Bekkum DW, Löwenberg B (eds). Bone Marrow Transplantation. Marcel Dekker: New York, 1985, pp 147-212.
2. Vogelsang VB, Hess AD. Graft-versus-host disease: new directions for a persistent problem. Blood 1994; 84: 2061-2067.
3. Gale RP, Bortin MM, Van Bekkum DW et al. Risk factors for acute graft-versus-host disease. Br J Haematol 1987; 67: 397-406.
4. Clift RA, Storb R. Histoincompatible bone marrow transplants in humans. Ann Rev Immunol 1987; 5: 43-64.
5. Anasetti C, Amos D, Beatty PG et al. Effect of HLA compatibility on engraftment of bone marrow transplantation in patients with leukemia or lymphoma. New Engl J Med 1989; 320: 197-204.
6. Goulmy E, Schipper R, Pool J et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. New Engl J Med 1996; 334: 281-285.
7. Vossen JM, Heidt PJ. Gnotobiotic measures for the prevention of acute graft-vs-host disease. In: Burakoff SJ, Deeg HJ, Ferrera J, Atkinson K (eds). Graft-vs-Host Disease. Marcel Dekker: New York, 1985, pp 403-413.
8. Heidt PJ, Vossen JM. Experimental and clinical gnotobiotics: Influence of the microflora on graft-versus-host disease after allogeneic bone marrow transplantation. J Med 1992; 23: 161-173.
9. Van Bekkum DW, Roodenburg J, Heidt PJ, Van der Waaij D. Mitigation of secondary disease of allogeneic mouse radiation chimeras by modification of the intestinal microflora. J Natl Cancer Inst 1974; 52: 401-404.
10. Storb R, Prentice RL, Buckner CD et al. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow graft from HLA-identical siblings; beneficial effect of a protective environment. New Engl J Med 1983; 308: 302-308.
11. Beelen DW, Haralambie E, Brandt H et al. Evidence that sustained growth suppression of intestinal anaerobic bacteria reduces the risk of acute graft-versus-host disease after sibling marrow transplantation. Blood 1992; 80: 2668-2676.
12. Billiau, A. Gamma-interferon: the match that lights the fire? Immunol Today 1988; 9: 37-40.
13. Smith SR, Terminelli C, Kenworthy-Bott L, Phillips LD. A study of cytokine production in acute graft-vs-host disease. Cell Immunol 1991; 134: 336-348.
14. Niederwieser D, Herold M, Woloszczuk W et al. Endogenous IFN-gamma during human bone marrow transplantation. Transplantation 1992; 50: 620-625.
15. Lampert IA, Suitters AJ, Chisholm PM. Expression of Ia antigen on epidermal keratinocytes in graft-versus-host disease. Nature 1981; 293: 149-150.
16. Mason DW, Dallman M, Barclay AH. Graft-versus-host disease induces expression of Ia antigen in rat epidermal cells and gut epithelium. Nature 1981; 293: 150-151.
17. Landolfo S, Cofano F, Giovarelli M et al. Inhibition of interferon-gamma may suppress allograft reactivity by T lymphocytes in vitro and in vivo. Science 1985; 229: 176-179.
18. Mowat AM. Antibodies to IFN-γ prevent immunological mediated intestinal damage in murine graft-versus-host reaction. Immunology 1989; 68: 18-23.
19. Brok HPM, Heidt PJ, Van der Meide PH et al. Interferon-γ prevents graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Immunol 1993; 151: 6451-6459.
20. Van den Engh G, Visser J, Trask B. Identification of CFU-s by scatter measurements on a light activated cell sorter. In: Baum SJ, Ledney GD (eds). Experimental Hematologv Today. Springer Verlag: New York, 1978, pp 19-26.
21. Zurcher C, Van Bekkum DW. Pathology of radiation chimeras. In: Van Bekkum DW, Löwenberg B (eds). Bone Marrow Transplantation, Biological Mechanisms and Clinical Practice. Marcel Dekker: New York, 1985. pp 213-310.
22. Belardelli F. Role of interferons and other cytokines in the regulation of the immune response. APMIS 1995; 103: 161-169.
23. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041-2050.
24. Slavin S, Naparstek E, Nagler A et al. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol 1995; 23: 1553-1562.
25. Sykes M, Szot GL, Nguyen PL, Pearson DA. Interleukin-12 inhibits murine graft-versus-host disease. Blood 1995; 86: 2429-2438.
26. Nestel FP, Price KS, Seemayer TA, Lapp WS. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor α during graft-versus-host disease. J Exp Med 1992; 175: 405-413.
27. Van Bekkum DW, Heidt PJ. The role of the microflora in graft-versus-host disease after allogeneic bone marrow transplantation. In: De Vries RRP, Cohen IR, Van Rood JJ (eds). The Role of Micro-organisms in Non-infectious Diseases. Springer Verlag: New York, 1990, pp 57-69.
28. Trinchieri G, Perussia B. Immune interferon: a pleiotropic lymphokine with multiple effects. Immunol Today 1985; 6: 131-136.
29. Skoskiewicz MJ, Colvin RB, Schneeberger EE, Russell PB. Widespread and selective induction of major histocompatibility complex-determined antigens in vivo by γ interferon. J Exp Med 1985; 162: 1645-1664.
30. Sykes M, Rommick ML, Hoyles KA, Sachs DH. In vivo administration of interleukin 2 plus T-cell depleted syngeneic marrow prevents graft-versus-host disease and permits alloen-graftment. J Exp Med 1990; 171: 645-658.
31. Sykes M, Abraham VS, Harty MW, Pearson PA. IL-2 reduces graft-vs-host disease and preserves a graft-vs-leukemia effect by selectively inhibiting CD4+ T cell activity. J Immunol 1993; 150: 197-205.
32. Szebeni J, Wang MG, Pearson DA et al. IL-2 inhibits early increases in serum gamma interferon levels associated with graft-versus-host disease. Transplantation 1995; 58: 1385-1393.
33. Trinchieri G. Interleukin-12 and its role in the generation of TH1 cells. Immunol Today 1993; 14: 335-338.
34. Germann T, Gately MK, Schoenhaut DS et al. Interleukin-12/T cell stimulating factor, a cytokine with multiple effects on T helper type 1 (Th1) but not on Th2 cells. Eur J Immunol 1993; 23: 1762-1770.
35. Gajewski TF, Goldwasser E, Fitch FW. Anti-proliferative effect of IFN-gamma in immune regulation. II. IFN-gamma inhibits the proliferation of murine bone marrow cells stimulated with IL-3, IL-4 or granulocyte-macrophage colony stimulating factor. J Immunol 1988; 141: 2635-2642.
36. Gajewski TF, Fitch FW. Anti-proliferative effect of IFN-gamma in immune regulation. I. IFN-gamma inhibits the proliferation of Th2 but not Th1 murine T lymphocyte clones. J Immunol 1988; 140: 4245-4252.
37. Tare NS, Bowen S, Warner RR et al. Administration of recombinant interleukin-12 to mice suppresses hematopoiesis in the bone marrow but enhances hematopoiesis in the spleen. J Interferon Cytokine Res 1995; 15: 377-383.
38. Godfrey, DI, Gately MK, Hakimi J et al. IL-12 influences intrathymic T cell development. J Immunol 1994; 152: 2729-2735.
39. Krenger, W Falzarano G, Delmonte J Jr et al. Interferon-gamma suppresses T-cell proliferation to mitogen via the nitric oxide pathway during experimental acute graft-versus-host disease. Blood 1996; 88: 1113-1121.